Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million
Femasys announced a $30 million private placement that could generate up to $90 million if warrants are fully exercised. The financing extends the company’s funding capacity but introduces dilution and leaves the longer-term value dependent on whether capital can accelerate a business with $2.3 million of revenue and a -812.3% net margin.
Femasys said it entered a securities purchase agreement with accredited investors for a $30 million private placement, led by new institutional investor Nantahala Capital. The company said potential proceeds could reach up to $90 million if the warrants are fully exercised.
The financing gives Femasys additional capital for its fertility and non-surgical permanent birth-control programs, while the warrant structure creates a possible future source of funds. Femasys reported $2.3 million of fiscal-year 2025 revenue, up 40.8% year over year, alongside a -812.3% net margin and $-0.47 diluted EPS.
That creates a two-sided setup for FEMY. The bull case is that the capital supports development, regulatory work, and commercialization around a growing revenue base; the bear case is that the financing adds dilution risk while the company remains deeply loss-making.
The next focus is the detailed terms of the securities and warrants, including exercise prices, use of proceeds, and any registration provisions. Investors will also need to track whether revenue growth continues and whether operating losses narrow as the new capital is deployed.
FEMY investors are weighing whether the $30 million placement’s funding runway and up to $90 million of potential warrant proceeds outweigh dilution and the company’s still-heavy losses.
The placement materially improves Femasys' access to capital, and the $2.3 million revenue base grew 40.8% year over year. However, the -812.3% net margin and $-0.47 diluted EPS show that the financing is also a response to substantial ongoing cash needs. Key details on warrant pricing and the number of new securities remain to be clarified.
The setup weakens if the warrant terms imply substantial near-term dilution or if the new capital fails to translate the 40.8% revenue growth into a narrowing loss profile.
CoverageSource: GlobeNewswire · Published here FRI, AUG 7 · 9:25 AM ET · the only report in this recordHow this is decided →
Earlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.
No later reports linked yet.
Follow this story to find new evidence in your Following desk.
Price context does not establish that the story caused the move.
The strongest bull case is that $30 million of immediate financing, with up to $90 million of potential proceeds, gives Femasys resources to build on $2.3 million of revenue growing 40.8% year over year.
The strongest bear case is that dilution and future warrant overhang arrive while Femasys still reports a -812.3% net margin and $-0.47 diluted EPS.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →